Abstract

Background Several studies have identified FcγRIIIb (Fcgr3b) polymorphisms that determine susceptibility to autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis. The objective of the study was to clarify whether FcγRIIIb allele polymorphism influence susceptibility to end stage renal disease (ESRD) patients with renal transplantation. Methods DNA fragments were amplified by PCR-SSP using genomic DNA from 172 unrelated, healthy blood donors and 171 renal recipients in our Kidney Disease Centre. We performed direct sequencing using 20 PCR products of renal recipients carrying different FcγRIIIb forms according to the allele-specific PCR. Results FcγRIIIb NA1/NA2 genotype frequency showed significant difference between renal recipients and healthy controls ( χ 2 = 19.3, P < 0.005). In addition, the allele frequency also showed significant difference between the two groups. Lower frequency of genotype FcγRIIIb NA1/NA1 was observed in renal recipients than in healthy controls ( χ 2 = 5.06, P = 0.024). In comparison with nonrejectors, rejectors displayed no significant defference of FcγRIIIb NA1/NA2 genotype frequency, as well as allele frequency. Conclusion FcγRIIIb NA1/NA2 heterozygote genotype frequency was increased in ESRD patients in Chinese. The present findings showed that FcγRIIIb genotype related to the disease susceptibility, although FcγRIIIb polymorphisms did not affect the acute rejection.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.